Clinical Trials Browser

Lymphoproliferative Disorders × Nivolumab × 30 days × Clear all

NCT03258567 2026-06-05

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections